‘Uberfication’ will change marketing and sales in the pharmaceutical sector, says Patrik Frei. This is already seen at healthcare companies, where digitalisation is making inroads. Business angels and family offices are paying an increasingly larger role in awarding venture capital, according to the CEO of Venture Valuation. Venture capitalists are coming aboard only later. What does Venture Valuation do? Patrik Frei: We conduct independent assessments of companies in the life sciences sector. Our clients are looking either for capital or investments. We then try to determine a fair value and indicate a range. The price is then, of course, a matter of negotiation. How do you rate Johnson & Johnson’s acquisition of Actelion – well negotiated or a fair value? Actelion was already a success s>>> More Information
Die Zukunft von Life sciences gestalten – BaselArea.swiss an der JPM17
Venture Philanthropy and Allschwil: Polyphor gets $3 Million from the Cystic Fibrosis Foun...
Piqur raises CHF 18 million in series A2 financing
CRISPR Therapeutics from Basel raises additional $64 million